GAMMA Investing’s Black Diamond Therapeutics BDTX Stock Holding History

GAMMA Investing’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.31K	Buy	+1,227	New	+$2.4K	﹤0.01%	3907

Other funds holding BDTX

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $716M AUM 16.7% 1-Year Est. Return

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

Kathmere Capital Management Wayne, Pennsylvania $2.07B AUM 20.3% 1-Year Est. Return

J. Safra Sarasin Holding $7.05B AUM 26.14% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing's BDTX Position: Q3 2026 in Review

GAMMA Investing opened a new position in Black Diamond Therapeutics (BDTX) in Q3 2026: 1,227 shares worth $2.31K. The stake represents ﹤0.01% of the portfolio and ranks #3907 among its holdings.

19 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

GAMMA Investing held 1,227 shares of Black Diamond Therapeutics worth $2.31K as of Q3 2026.
Black Diamond Therapeutics was a new GAMMA Investing position in Q3 2026.
Black Diamond Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3907 holding.
19 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.